Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 67 Genitourinary 31 Gynecologic 26 Head & Neck 15 Endocrine 12 Dermatologic 11 Thoracic 9 Breast 8 CNS 6 Sarcoma 5 NET 5 Tumor-Agnostic 4 Other solid neoplasm 3 Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

venetoclax 304 Cyclophosphamide 229 Cytarabine 199 Azacitidine 187 fludarabine 180 Specimen Handling 136 Biopsy 103 fludarabine phosphate 97 Methotrexate 81 Rituximab 78 Daunorubicin 77 Dexamethasone 75 Vincristine 68 Whole-Body Irradiation 64 Mycophenolic Acid 59 Decitabine 57 Tacrolimus 55 Etoposide 52 ibrutinib 51 blinatumomab 51 Granulocyte Colony-Stimulating Factor 51 Busulfan 50 obinutuzumab 49 Prednisone 49 Melphalan 48 acalabrutinib 45 Idarubicin 45 Stem Cell Transplantation 44 Injections 44 Magnetic Resonance Spectroscopy 43

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

lenvatinib × Other hematologic neoplasm × 1 year × Clear all

NCT03486873 2026-06-05

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡